Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1970
Nomenclature: cyclin dependent kinase 17
Abbreviated Name: CDK17
Family: TAIRE subfamily
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 523 | 12q23.1 | CDK17 | cyclin dependent kinase 17 | |
Mouse | - | 523 | 10 C2 | Cdk17 | cyclin dependent kinase 17 | |
Rat | - | 523 | 7q13 | Cdk17 | cyclin-dependent kinase 17 |
Previous and Unofficial Names |
PCTAIRE protein kinase 2 | PCTAIRE2 | cyclin-dependent kinase 17 |
Database Links | |
Alphafold | Q00537 (Hs), Q8K0D0 (Mm), O35831 (Rn) |
BRENDA | 2.7.11.22 |
ChEMBL Target | CHEMBL5790 (Hs) |
Ensembl Gene | ENSG00000059758 (Hs), ENSMUSG00000020015 (Mm), ENSRNOG00000004148 (Rn) |
Entrez Gene | 5128 (Hs), 237459 (Mm), 314743 (Rn) |
Human Protein Atlas | ENSG00000059758 (Hs) |
KEGG Enzyme | 2.7.11.22 |
KEGG Gene | hsa:5128 (Hs), mmu:237459 (Mm), rno:314743 (Rn) |
OMIM | 603440 (Hs) |
Pharos | Q00537 (Hs) |
RefSeq Nucleotide | NM_001170464 (Hs), NM_146239 (Mm), NM_001108082 (Rn) |
RefSeq Protein | NP_002586 (Hs), NP_666351 (Mm), NP_001101552 (Rn) |
UniProtKB | Q00537 (Hs), Q8K0D0 (Mm), O35831 (Rn) |
Wikipedia | CDK17 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: PCTK2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
TAIRE subfamily: cyclin dependent kinase 17. Last modified on 20/03/2013. Accessed on 17/01/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1970.